Detalles de la búsqueda
1.
Autoimmunity Against Surfactant Protein B Is Associated with Pneumonitis During Checkpoint Blockade.
Am J Respir Crit Care Med
; 2024 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38626354
2.
Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients.
Cancer Immunol Immunother
; 70(2): 563-568, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-32804246
3.
BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors.
J Am Acad Dermatol
; 82(4): 854-861, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31449902
4.
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC).
Cancer Immunol Immunother
; 67(12): 1825-1832, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30171269
5.
Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease.
Cancer Immunol Immunother
; 67(1): 39-45, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28894934
6.
Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.
Hematol Oncol
; 36(1): 84-92, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-28621491
7.
Outcome of mantle cell lymphoma patients treated at a single institution over the past decade.
Hematol Oncol
; 32(4): 192-6, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24338732
8.
Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors.
Med
; 4(2): 113-129.e7, 2023 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36693381
9.
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
Br J Cancer
; 116(8): e15, 2017 04 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28324885
10.
Mycophenolate mofetil as second line treatment in autoimmune hepatitis - A retrospective single center analysis.
J Transl Autoimmun
; 5: 100172, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36451933
11.
C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer.
J Immunother Cancer
; 10(3)2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35292517
12.
Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
J Cancer Res Clin Oncol
; 148(3): 647-656, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34874490
13.
Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade.
Sci Immunol
; 7(75): eabn9644, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36054337
14.
Accelerated Course of Alveolar Echinococcosis After Treatment With Steroids in a Patient With Autoimmune Encephalitis.
Cureus
; 13(10): e18831, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34820209
15.
First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor.
J Cancer Res Ther
; 17(1): 276-278, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33723170
16.
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs.
JAMA Netw Open
; 4(3): e210380, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33651108
17.
Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
J Immunother Cancer
; 9(5)2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33986126
18.
Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.
ESMO Open
; 5(4)2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32641348
19.
Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project.
ESMO Open
; 4(6): e000596, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31803503
20.
Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment.
J Immunother
; 42(3): 89-93, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30768543